Bavarian Nordic to raise €387m to fund GSK vaccines purchase

Aidan Gregory

March 06, 2020 03:45 pm

Copenhagen_PA_575_375 — February 8, 2015, Copenhagen, Capital Region of Denmark, Denmark: Nyhavn, The Famous Waterfront Canal In Copenhagen With Colourful Seventeenth And Eighteenth Century Townhomes Lining The Canal At Dusk; Copenhagen, Denmark (Credit Image: © Micah Wright/Design Pics via ZUMA Wire) | Micah Wright/Zuma Press/PA Images

Danish pharmaceuticals company Bavarian Nordic has announced an Nkr2.8bn (€378m) rights issue to fund its acquisition of GlaxoSmithKline’s commercial and manufacturing rights to Rabipur, a treatment for rabies, and Encepur, a vaccine against tick-borne encephalitis.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Nordics Health and Biotech Denmark Equity Europe Follow-ons and Rights issues EMEA SRI Nordea Markets

AG

Aidan Gregory